• 1.遵義醫(yī)學院(貴州遵義 563003);;
  • 2.四川省醫(yī)學科學院·四川省人民醫(yī)院乳腺外科(四川成都 610072);

目的  總結(jié)目前對妊娠期乳腺癌診斷與治療的相關(guān)研究,為妊娠期乳腺癌的診斷與治療提供參考依據(jù)。
方法  應用PubMed、Medline和CNKI以“妊娠期乳腺癌、妊娠期乳腺癌的診斷、妊娠期乳腺癌的治療”等為關(guān)鍵詞,檢索關(guān)于妊娠期乳腺癌的診斷與治療的相關(guān)文獻并進行綜述。
結(jié)果  妊娠期乳腺癌的診斷手段包括彩超、鉬靶、核磁共振、穿刺活檢等,其治療包括了手術(shù)治療、化學治療、內(nèi)分泌治療、放射治療、靶向治療。但是診斷和治療手段的使用要考慮到是否對妊娠患者及胎兒的影響。
結(jié)論  通過對相關(guān)妊娠期乳腺癌診斷和治療的研究分析,可以為妊娠期乳腺癌患者妊娠提供安全且合理的診斷和治療措施,貝伐單抗及拉帕替尼在妊娠期乳腺癌治療中的使用有待進一步研究。

引用本文: 黃元坤,周蕾蕾. 妊娠期乳腺癌的診斷和治療現(xiàn)狀. 中國普外基礎(chǔ)與臨床雜志, 2013, 20(8): 862-866. doi: 復制

1. Pentheroudakis G, Orecchia R, Hoekstra HJ, et al. Cancer, fertility and pregnancy:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 21 Suppl 5:v266-v273.
2. Middleton LP, Amin M, Gwyn K, et al. Breast carcinoma in pregnant women:assessment of clinicopathologic and immunohistochemical features[J]. Cancer, 2003, 98(5):1055-1060.
3. Bonnier P, Romain S, Dilhuydy JM, et al. Influence of pregnancy on the outcome of breast cancer:a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group[J]. Int J Cancer, 1997, 72(5):720-727.
4. Greskovich JF, Macklis RM. Radiation therapy in pregnancy:risk calculation and risk minimization[J]. Semin Oncol, 2000, 27(6):633-645.
5. Osei EK, Faulkner K. Fetal doses from radiological examinations[J]. Br J Radiol, 1999, 72(860): 773-780.
6. Yang WT, Dryden MJ, Gwyn K, et al. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy[J]. Radiology, 2006, 239(1):52-60.
7. 沈鎮(zhèn)宙, 邵志敏. 乳腺腫瘤學[M]. 上海:上海科學技術(shù)出版社, 2005: 92 -121.
8. Vashi R, Hooley R, Butler R, et al. Breast imaging of the pregnant and lactating patient:imaging modalities and pregnancy-asso-ciated breast cancer[J]. AJR Am J Roentgenol, 2013, 200(2):321-328.
9. NCCN Clinical Practice Guidelines in Oncology. Breast cancer[EB/OL]. Version 2. 2012. Available online:http://www. nccn.com.
10. Rovera F, Frattini F, Coglitore A, et al. Breast cancer in pregnancy[J]. Breast J, 2010, 16 Suppl 1:S22-S25.
11. Molckovsky A, Madarnas Y. Breast cancer in pregnancy:a literature review [J]. Breast Cancer Res Treat, 2008, 108(3):333-338.
12. Navrozoglou I, Vrekoussis T, Kontostolis E, et al. Breast cancer during pregnancy:a mini-review[J]. Eur J Surg Oncol, 2008, 34(8):837-843.
13. Vinatier E, Merlot B, Poncelet E, et al. Breast cancer duringpregnancy[J]. Eur J Obstet Gynecol Reprod Biol, 2009, 147(1):9-14.
14. Amant F, Loibl S, Neven P, et al. Breast cancer in pregnancy[J]. Lancet, 2012, 379(9815):570-579.
15. Gentilini O, Cremonesi M, Trifirò G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer[J]. Ann Oncol, 2004, 15(9):1348-1351.
16. Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer[J]. Eur J Nucl Med Mol Imaging, 2010, 37(1):78-83.
17. Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping[J]. Breast J, 2008, 14(3):250-254.
18. Azim H Jr, Gentilini O, Locatelli M, et al. Managing pregnant women with cancer:personal considerations and a review of the literature[J]. Ecancermedicalscience, 2011, 5:204.
19. Behrman RH, Homer MJ, Yang WT, et al. Mammography and fetal dose[J]. Radiology, 2007, 243(2):605-606.
20. Martin DD. Review of radiation therapy in the pregnant cancer patient[J]. Clin Obstet Gynecol, 2011, 54(4):591-601.
21. Guidroz JA, Scott-Conner CE, Weigel RJ. Management of pregnant women with breast cancer[J]. Surg Oncol, 2011, 103(4):337-340.
22. Amant F, Deckers S, Van Calsteren K, et al. Breast cancer in pregnancy:recommendations of an international consensus meeting[J]. Eur J Cancer, 2010, 46(18):3158-3168.
23. Ring AE, Smith IE, Jones A, et al. Chemotherapy for breast cancer during pregnancy:an 18-year experience from five Londonteaching hospitals[J]. Clin Oncol, 2005, 23(18):4192-4197.
24. Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnantbreast cancer patients and outcomes of children exposed to chemo-therapy in utero[J]. Cancer, 2006, 107(6):1219-1226.
25. Azim HA Jr, Peccatori FA, Pavlidis N. Treatment of the pregnantmother with cancer:a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. PartⅠ:Solid tumors[J]. Cancer Treat Rev, 2010, 36(2):101-109.
26. Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting[J]. Cancer, 2006, 106(2):237-246.
27. Zagouri F, Sergentanis TN, Chrysikos D, et al. Taxanes for breast cancer during pregnancy:a systematic review[J]. Clin Breast Cancer, 2013, 13(1):16-23.
28. Cardonick E, Bhat A, Gilmandyar D, et al. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy:case series and review of the literature[J]. Ann Oncol, 2012, 23(12):3016-3023.
29. Berveiller P, Mir O. Taxanes during pregnancy:probably safe, but still to be optimized[J]. Oncology, 2012, 83(4):239-240.
30. Azim HA, Del Mastro L, Scarfone G, et al. Treatment of breast cancer during pregnancy:regimen selection, pregnancy monitoringand more[J]. Breast, 2011, 20(1):1-6.
31. Azim HA, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies:a real challenge[J]. Expert Rev Clin Immunol, 2010, 6(6):821-826.
32. Zagouri F, Sergentanis TN, Chrysikos D, et al. Trastuzumab administration during pregnancy:a systematic review and meta-analysis[J]. Breast Cancer Res Treat, 2013, 137(2):349-357.
33. Goodyer MJ, Ismail JR, O’Reilly SP, et al. Safety of trastuzumab(Herceptin?) during pregnancy:two case reports[J]. Cases J, 2009, 2:9329.
34. Waterston AM, Graham J. Effect of adjuvant trastuzumab on pregnancy[J]. Clin Oncol, 2006, 24(2):321-322.
35. Azim HA, Peccatori FA, Liptrott SJ, et al. Breast cancer and pregnancy:how safe is trastuzumab?[J]. Nat Rev Clin Oncol, 2009, 6(6):367-370.
36. Pentsuk N, van der Laan JW. An interspecies comparison of plac-ental antibody transfer:new insights into developmental toxicity testing of monoclonal antibodies[J]. Birth Defects Res B Dev Reprod Toxicol, 2009, 86(4):328-344.
37. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuz-umab after adjuvant chemotherapy in HER2-positive breast cancer[J]. N Engl J Med, 2005, 353(16):1659-1672.
38. Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer[J]. Cancer, 2010, 116(4):791-798.
39. Azim HA Jr, Metzger-Filho O, de Azambuja E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)[J]. Breast Cancer Res Treat, 2012, 133(1):387-391.
40. Kelly H, Graham M, Humes E, et al. Delivery of a healthy baby after first-trimester maternal exposure to lapatinib[J]. Clin Breast Cancer, 2006, 7(4):339-341.
41. Braems G, Denys H, De Wever O, et al. Use of tamoxifen before and during pregnancy[J]. Oncologist, 2011, 16(11):1547-1551.
42. Tiboni GM, Marotta F, Rossi C, et al. Effects of the aromataseinhibitor letrozole on in utero development in rats[J]. Hum Reprod,.
43. , 23(8):1719-1723.
  1. 1. Pentheroudakis G, Orecchia R, Hoekstra HJ, et al. Cancer, fertility and pregnancy:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 21 Suppl 5:v266-v273.
  2. 2. Middleton LP, Amin M, Gwyn K, et al. Breast carcinoma in pregnant women:assessment of clinicopathologic and immunohistochemical features[J]. Cancer, 2003, 98(5):1055-1060.
  3. 3. Bonnier P, Romain S, Dilhuydy JM, et al. Influence of pregnancy on the outcome of breast cancer:a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group[J]. Int J Cancer, 1997, 72(5):720-727.
  4. 4. Greskovich JF, Macklis RM. Radiation therapy in pregnancy:risk calculation and risk minimization[J]. Semin Oncol, 2000, 27(6):633-645.
  5. 5. Osei EK, Faulkner K. Fetal doses from radiological examinations[J]. Br J Radiol, 1999, 72(860): 773-780.
  6. 6. Yang WT, Dryden MJ, Gwyn K, et al. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy[J]. Radiology, 2006, 239(1):52-60.
  7. 7. 沈鎮(zhèn)宙, 邵志敏. 乳腺腫瘤學[M]. 上海:上??茖W技術(shù)出版社, 2005: 92 -121.
  8. 8. Vashi R, Hooley R, Butler R, et al. Breast imaging of the pregnant and lactating patient:imaging modalities and pregnancy-asso-ciated breast cancer[J]. AJR Am J Roentgenol, 2013, 200(2):321-328.
  9. 9. NCCN Clinical Practice Guidelines in Oncology. Breast cancer[EB/OL]. Version 2. 2012. Available online:http://www. nccn.com.
  10. 10. Rovera F, Frattini F, Coglitore A, et al. Breast cancer in pregnancy[J]. Breast J, 2010, 16 Suppl 1:S22-S25.
  11. 11. Molckovsky A, Madarnas Y. Breast cancer in pregnancy:a literature review [J]. Breast Cancer Res Treat, 2008, 108(3):333-338.
  12. 12. Navrozoglou I, Vrekoussis T, Kontostolis E, et al. Breast cancer during pregnancy:a mini-review[J]. Eur J Surg Oncol, 2008, 34(8):837-843.
  13. 13. Vinatier E, Merlot B, Poncelet E, et al. Breast cancer duringpregnancy[J]. Eur J Obstet Gynecol Reprod Biol, 2009, 147(1):9-14.
  14. 14. Amant F, Loibl S, Neven P, et al. Breast cancer in pregnancy[J]. Lancet, 2012, 379(9815):570-579.
  15. 15. Gentilini O, Cremonesi M, Trifirò G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer[J]. Ann Oncol, 2004, 15(9):1348-1351.
  16. 16. Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer[J]. Eur J Nucl Med Mol Imaging, 2010, 37(1):78-83.
  17. 17. Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping[J]. Breast J, 2008, 14(3):250-254.
  18. 18. Azim H Jr, Gentilini O, Locatelli M, et al. Managing pregnant women with cancer:personal considerations and a review of the literature[J]. Ecancermedicalscience, 2011, 5:204.
  19. 19. Behrman RH, Homer MJ, Yang WT, et al. Mammography and fetal dose[J]. Radiology, 2007, 243(2):605-606.
  20. 20. Martin DD. Review of radiation therapy in the pregnant cancer patient[J]. Clin Obstet Gynecol, 2011, 54(4):591-601.
  21. 21. Guidroz JA, Scott-Conner CE, Weigel RJ. Management of pregnant women with breast cancer[J]. Surg Oncol, 2011, 103(4):337-340.
  22. 22. Amant F, Deckers S, Van Calsteren K, et al. Breast cancer in pregnancy:recommendations of an international consensus meeting[J]. Eur J Cancer, 2010, 46(18):3158-3168.
  23. 23. Ring AE, Smith IE, Jones A, et al. Chemotherapy for breast cancer during pregnancy:an 18-year experience from five Londonteaching hospitals[J]. Clin Oncol, 2005, 23(18):4192-4197.
  24. 24. Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnantbreast cancer patients and outcomes of children exposed to chemo-therapy in utero[J]. Cancer, 2006, 107(6):1219-1226.
  25. 25. Azim HA Jr, Peccatori FA, Pavlidis N. Treatment of the pregnantmother with cancer:a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. PartⅠ:Solid tumors[J]. Cancer Treat Rev, 2010, 36(2):101-109.
  26. 26. Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting[J]. Cancer, 2006, 106(2):237-246.
  27. 27. Zagouri F, Sergentanis TN, Chrysikos D, et al. Taxanes for breast cancer during pregnancy:a systematic review[J]. Clin Breast Cancer, 2013, 13(1):16-23.
  28. 28. Cardonick E, Bhat A, Gilmandyar D, et al. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy:case series and review of the literature[J]. Ann Oncol, 2012, 23(12):3016-3023.
  29. 29. Berveiller P, Mir O. Taxanes during pregnancy:probably safe, but still to be optimized[J]. Oncology, 2012, 83(4):239-240.
  30. 30. Azim HA, Del Mastro L, Scarfone G, et al. Treatment of breast cancer during pregnancy:regimen selection, pregnancy monitoringand more[J]. Breast, 2011, 20(1):1-6.
  31. 31. Azim HA, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies:a real challenge[J]. Expert Rev Clin Immunol, 2010, 6(6):821-826.
  32. 32. Zagouri F, Sergentanis TN, Chrysikos D, et al. Trastuzumab administration during pregnancy:a systematic review and meta-analysis[J]. Breast Cancer Res Treat, 2013, 137(2):349-357.
  33. 33. Goodyer MJ, Ismail JR, O’Reilly SP, et al. Safety of trastuzumab(Herceptin?) during pregnancy:two case reports[J]. Cases J, 2009, 2:9329.
  34. 34. Waterston AM, Graham J. Effect of adjuvant trastuzumab on pregnancy[J]. Clin Oncol, 2006, 24(2):321-322.
  35. 35. Azim HA, Peccatori FA, Liptrott SJ, et al. Breast cancer and pregnancy:how safe is trastuzumab?[J]. Nat Rev Clin Oncol, 2009, 6(6):367-370.
  36. 36. Pentsuk N, van der Laan JW. An interspecies comparison of plac-ental antibody transfer:new insights into developmental toxicity testing of monoclonal antibodies[J]. Birth Defects Res B Dev Reprod Toxicol, 2009, 86(4):328-344.
  37. 37. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuz-umab after adjuvant chemotherapy in HER2-positive breast cancer[J]. N Engl J Med, 2005, 353(16):1659-1672.
  38. 38. Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer[J]. Cancer, 2010, 116(4):791-798.
  39. 39. Azim HA Jr, Metzger-Filho O, de Azambuja E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)[J]. Breast Cancer Res Treat, 2012, 133(1):387-391.
  40. 40. Kelly H, Graham M, Humes E, et al. Delivery of a healthy baby after first-trimester maternal exposure to lapatinib[J]. Clin Breast Cancer, 2006, 7(4):339-341.
  41. 41. Braems G, Denys H, De Wever O, et al. Use of tamoxifen before and during pregnancy[J]. Oncologist, 2011, 16(11):1547-1551.
  42. 42. Tiboni GM, Marotta F, Rossi C, et al. Effects of the aromataseinhibitor letrozole on in utero development in rats[J]. Hum Reprod,.
  43. 43. , 23(8):1719-1723.